Last reviewed · How we verify
Topamax® Sprinkle Capsules 25 mg
At a glance
| Generic name | Topamax® Sprinkle Capsules 25 mg |
|---|---|
| Sponsor | Mylan Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Topiramate 25 mg Capsules Under Fasting Conditions (PHASE1)
- Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg (PHASE1)
- Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg (PHASE1)
- Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topamax® Sprinkle Capsules 25 mg CI brief — competitive landscape report
- Topamax® Sprinkle Capsules 25 mg updates RSS · CI watch RSS
- Mylan Pharmaceuticals Inc portfolio CI